Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.30 |
| ▸ | BACE1 | P56817 | 2/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13059010 | 0.93 | ADRB3 (0.43) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13026168 | 0.92 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13646607 | 0.92 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL8026934 | 0.92 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL12315733 | 0.92 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL10254639 | 0.92 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL10254433 | 0.91 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4BACE1 | |
| SCHEMBL7924768 | 0.91 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4BACE1 | |
| SCHEMBL8320089 | 0.91 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL8037005 | 0.91 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299021-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8263549-B2 | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | ARRAY BIOPHARMA, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2305696-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7829665-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829665-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090175822-A1 | C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2007015824-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | ADRB3 4572/4885ADRA2B 4492/4885ADRA2C 4004/4885 |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | ADRB3 4572/4885ADRA2B 4492/4885ADRA2C 4004/4885 |
| US-20090175822-A1 | C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PREP, PRSS1, CTSC | ADRB3 4570/4885ADRA2B 4720/4885ADRA2C 4195/4885 |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | ADRB3 4572/4885ADRA2B 4492/4885ADRA2C 4004/4885 |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | EIF2AK2, HAVCR2, HCCS | ADRB3 4531/4885ADRA2B 4489/4885ADRA2C 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.